The DDD-monitoring of consumption of fluoroquinolones when treating community-acquired pneumonia in a multi-specialty hospital in the Republic of Tajikistan

Authors

  • L. V. Savchenkova Tajik National University, Tajikistan
  • M. N. Saidova Tajik National University, Tajikistan
  • N. S. Sanginova Tajik National University, Tajikistan

DOI:

https://doi.org/10.24959/nphj.17.2177

Keywords:

pharmacoepidemiology, fluoroquinolones, community-acquired pneumonia

Abstract

Community-acquired pneumonia is one of the most common diseases and is still the leading cause of death among infectious diseases. Such drugs as β-lactam antibiotics, new macrolides (azithromycin, clarithromycin) and respiratory fluoroquinolones are of the greatest importance in the treatment of community-acquired pneumonia in adult patients worldwide.

Aim. To analyze and assess the dynamics of consumption of fluoroquinolones for the treatment of community-acquired pneumonia in a multi-specialty hospital in the Republic of Tajikistan using the DDD-methodology.

Materials and methods. A retrospective descriptive analysis of medical prescriptions for pharmacotherapy of patients treated in the Pulmonology department of the Sogdigh Regional Clinical Hospital (Khujand, Republic of Tajikistan) was performed. The consumption of fluoroquinolones was estimated according to the ATC/DDD index of the WHO. The unit of measurement used was the number of grams of the active substance with further calculation of the DDD/100 bed-days and % of the total DDD.

Results and discussion. The DDD analysis of consumption of fluoroquinolones in the Pulmonology department of the multi-specialty hospital showed a significant change in the structure of consumption of this group of drugs for the initial antibiotic therapy of community-acquired pneumonia in the last five years. A clear tendency was observed to reduce the consumption of this class of drugs in 2011-2015. There is a significant reduction in the consumption of ofloxacin and levofloxacin against the background of a slight tendency to increase the demand for ciprofloxacin in the treatment of pneumonia in the inpatient drug treatment.

Conclusions. Monitoring of the consumption of antimicrobial drugs from the fluoroquinolone group for the treatment of community-acquired pneumonia in the Pulmonology department of the multi-specialty hospital using the ATS/DDD-methodology makes it possible to assess the tactics of community-acquired pneumonia treatment in this region, its compliance with the international standards and the risks of developing the drug-resistant microflora, in particular to fluoroquinolones.

Author Biographies

L. V. Savchenkova, Tajik National University

Doctor of Medicine (Dr. habil.), professor, head of the Department of Pharmacy

M. N. Saidova, Tajik National University

Candidate of Pharmacy (PhD), associate professor of the Department of Pharmacy

N. S. Sanginova, Tajik National University

teaching assistant of the Department of Pharmacy

References

Rozenbaum, M. H., Pechlivanoglou, P., Werf, T. S., Lo–Ten–Foe, J. R., Postma, M. J., Hak, E. (2012). The role of Streptococcus pneumoniae in community–acquired pneumonia among adults in Europe: a meta–analysis. European Journal of Clinical Microbiology & Infectious Diseases, 32 (3), 305–316. doi: 10.1007/s10096–012–1778–4

2. Agentstvo po statistike pri Prezidente Respubliki Tadzhikistan (2013).Dushanbe, 62.

Kaiumov, Kh. B. (2009). Osobennosti etiologicheskoi struktury bronkholegochnykh zabolevanii u naseleniia Resbubliki Tadzhikistan na sovremennom etape.Dushanbe, 115.

Oralbekova, Zh. M. (2013). Kliniko–morfologicheskie osobennosti i prediktory neblagopriiatnogo prognoza pri vnebolnichnoi pnevmonii, 25.

Baranov, A. A., Namazova–Baranova, L. S., Maianskii, N. A. (2013). Pediatricheskaia farmakologiia – Pediatric pharmacology, 5 (10), 6–12.

Chuchalin, A. G., Sinopalnikov, A. I., Kozlov, R. S. (2013). Infektcionnye bolezni: novosti, mneniia, obuchenie, 2 (3), 91–123.

ESAC Final Management Report 2009–2010 (2010). European Surveillance of Antimicrobial Consumption,153.

Chen, Y., Deng, W., Wang, S.–M., Mo, Q.–M., Jia, H., Wang, Q., Wang, X.–Y. (2011). Burden of Pneumonia and Meningitis Caused by Streptococcus pneumoniae in Chinaamong Children under 5 Years of Age: A Systematic Literature Review. PLoS ONE, 6 (11), e27333. doi: 10.1371/journal.pone.0027333

Bova, A. A. (2017). Voennaia meditcina, 2 (43), 98–109.

Sidorenko, S. V. (2011). Trudnyi patcient, 5 (9), 21–27.

Khamitov, R. F., Nikitina, R. B. (2011). Kazanskii meditcinskii zhurnal – Kazan medical journal, 1 (92), 1–4.

Albertson, T. E., Morrissey, B. M., Chan, A. L. (2012). Are Fluoroquinolones Superior Antibiotics for the Treatment of Community–Acquired Pneumonia? Current Infectious Disease Reports, 14 (3), 317–329. doi: 10.1007/s11908–012–0251–y

Léophonte, P. (2001). New generation fluoroquinolones and the treatment of adults with community–acquired pneumonia. Medecine et Maladies Infectieuses, 5 (31), 648–652.

Sinopalnikov, A. I. (2012). Spravochnik poliklinicheskogo vracha, 1, 47–53.

Sinopalnikov, A. I. (2016). Klinicheskaia meditcina, 11 (94), 851–860.

Sinopalnikov, A. I., Zaitcev, A. A. (2011). Spravochnik poliklinicheskogo vracha, 3, 16–21.

Blasi, F., Piffer, F., Zanardelli, M. et al. (2012). The role of fluoroquinolones in the treatment of patients hospitalised with community–acquired pneumonia. European Respiratory Disease, 1 (8), 61–65.

18. About ATC/DDD system. Available at: http://www. whocc.no/atc ddd

Shams, W. E., Evans, M. E. (2005). Guide to Selection of Fluoroquinolones in Patients with Lower Respiratory Tract Infections. Drugs, 65 (7), 949–991. doi: 10.2165/00003495–200565070–00004

Jones, M., Draghi, D., Thornsberry, C., Sahm, D. (2006). A current perspective on S.pneumoniae and H.influenzae resistance trends in Europe : GLOBAL Surveillance Study, 2005, 1629.

Bolieva, L. Z., Tcallagova, O. T., Gatagonova, T. M. (2014). Vladikavkazskii mediko–biologicheskii vestnik, 30 (20), 105–108.

Downloads

Published

2017-12-04

Issue

No. 4(92) (2017)

Section

Organization and Economy of Pharmacy

License

Copyright (c) 2017 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).